Alaunos Therapeutics, Inc. Research and Development Expense
Alaunos Therapeutics, Inc. (TCRT) reported Research and Development Expense of $388.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Alaunos Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $388.00K, a 109.73% increase year-over-year.
- Alaunos Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $427.00K, a 23.05% increase year-over-year.
- Alaunos Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $361.00K.
- Alaunos Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $469.00K, a 227.97% increase year-over-year.
- Alaunos Therapeutics, Inc. research and development expense for fiscal 2025 was $1.36M, a 276.52% increase from fiscal 2024.
- Alaunos Therapeutics, Inc. research and development expense for fiscal 2024 was $362.00K, a 97.78% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. research and development expense for fiscal 2023 was $16.28M, a 34.93% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. research and development expense for fiscal 2022 was $25.02M, a 49.60% decline from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 100 month | Research and Development Expense 103 month | Research and Development Expense 106 month | Research and Development Expense 109 month | Research and Development Expense 112 month | Research and Development Expense 115 month | Research and Development Expense 118 month | Research and Development Expense 121 month | Research and Development Expense 124 month | Research and Development Expense 127 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $388.00K 10-Q · filed 2026-08-14 | $814.00K 10-Q · filed 2026-08-14 | $1.18M derived: sum of 3 quarters · filed 2026-08-14 | $1.65M derived: sum of 4 quarters · filed 2026-08-14 | |||||||||||
| 2026-03-31 | $427.00K 10-Q · filed 2026-05-15 | $788.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.26M derived: sum of 3 quarters · filed 2026-05-15 | $1.44M derived: sum of 4 quarters · filed 2026-08-14 | |||||||||||
| 2025-12-31 | $361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $830.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.01M derived: sum of 3 quarters · filed 2026-08-14 | $1.36M 10-K · filed 2026-03-31 | |||||||||||
| 2025-09-30 | $469.00K 10-Q · filed 2025-11-14 | $654.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.00M 10-Q · filed 2025-11-14 | $915.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||||||||
| 2025-06-30 | $185.00K 10-Q · filed 2026-08-14 | $531.00K 10-Q · filed 2026-08-14 | $446.00K derived: sum of 3 quarters · filed 2026-08-14 | $589.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||||||||
| 2025-03-31 | $347.00K 10-Q · filed 2026-05-15 | $261.00K derived: sum of 2 quarters · filed 2026-05-15 | $404.00K derived: sum of 3 quarters · filed 2026-05-15 | $584.00K derived: sum of 4 quarters · filed 2026-05-15 | |||||||||||
| 2024-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $57.00K derived: sum of 2 quarters · filed 2026-03-31 | $237.00K derived: sum of 3 quarters · filed 2026-03-31 | $362.00K 10-K · filed 2026-03-31 | |||||||||||
| 2024-09-30 | $143.00K 10-Q · filed 2025-11-14 | $323.00K derived: sum of 2 quarters · filed 2025-11-14 | $448.00K 10-Q · filed 2025-11-14 | $1.38M derived: sum of 4 quarters · filed 2025-11-14 | |||||||||||
| 2024-06-30 | $180.00K 10-Q · filed 2025-08-14 | $306.00K 10-Q · filed 2025-08-14 | $1.24M derived: sum of 3 quarters · filed 2025-08-14 | $4.89M derived: sum of 4 quarters · filed 2025-08-14 | |||||||||||
| 2024-03-31 | $126.00K 10-Q · filed 2025-05-15 | $1.06M derived: sum of 2 quarters · filed 2025-05-15 | $4.71M derived: sum of 3 quarters · filed 2025-05-15 | $9.90M derived: sum of 4 quarters · filed 2025-05-15 | |||||||||||
| 2023-12-31 | $933.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.59M derived: sum of 2 quarters · filed 2025-03-31 | $9.78M derived: sum of 3 quarters · filed 2025-03-31 | $16.28M 10-K · filed 2025-03-31 | |||||||||||
| 2023-09-30 | $3.66M 10-Q · filed 2024-11-14 | $8.84M derived: sum of 2 quarters · filed 2024-11-14 | $15.35M 10-Q · filed 2024-11-14 | $20.95M derived: sum of 4 quarters · filed 2024-11-14 | |||||||||||
| 2023-06-30 | $5.19M 10-Q · filed 2024-08-14 | $11.69M 10-Q · filed 2024-08-14 | $17.30M derived: sum of 3 quarters · filed 2024-08-14 | $25.19M derived: sum of 4 quarters · filed 2024-08-14 | |||||||||||
| 2023-03-31 | $6.50M 10-Q · filed 2024-05-15 | $12.11M derived: sum of 2 quarters · filed 2024-05-15 | $20.00M derived: sum of 3 quarters · filed 2024-05-15 | $25.94M derived: sum of 4 quarters · filed 2024-05-15 | |||||||||||
| 2022-12-31 | $5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $13.50M derived: sum of 2 quarters · filed 2024-04-01 | $19.44M derived: sum of 3 quarters · filed 2024-04-01 | $25.02M 10-K · filed 2024-04-01 | |||||||||||
| 2022-09-30 | $7.89M 10-Q · filed 2023-11-14 | $13.83M derived: sum of 2 quarters · filed 2023-11-14 | $19.41M 10-Q · filed 2023-11-14 | $27.63M derived: sum of 4 quarters · filed 2023-11-14 | |||||||||||
| 2022-06-30 | $5.94M 10-Q · filed 2023-08-14 | $11.52M 10-Q · filed 2023-08-14 | $19.73M derived: sum of 3 quarters · filed 2023-08-14 | $34.25M derived: sum of 4 quarters · filed 2023-08-14 | |||||||||||
| 2022-03-31 | $5.58M 10-Q · filed 2023-05-10 | $13.80M derived: sum of 2 quarters · filed 2023-05-10 | $28.32M derived: sum of 3 quarters · filed 2023-05-10 | $41.89M derived: sum of 4 quarters · filed 2023-05-10 | |||||||||||
| 2021-12-31 | $8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $22.74M derived: sum of 2 quarters · filed 2023-03-07 | $36.31M derived: sum of 3 quarters · filed 2023-03-07 | $49.64M 10-K · filed 2023-03-07 | |||||||||||
| 2021-09-30 | $14.52M 10-Q · filed 2022-11-14 | $28.09M derived: sum of 2 quarters · filed 2022-11-14 | $41.43M 10-Q · filed 2022-11-14 | $55.40M derived: sum of 4 quarters · filed 2022-11-14 | |||||||||||
| 2021-06-30 | $13.57M 10-Q · filed 2022-08-15 | $26.91M 10-Q · filed 2022-08-15 | $40.88M derived: sum of 3 quarters · filed 2022-08-15 | $54.84M derived: sum of 4 quarters · filed 2022-08-15 | |||||||||||
| 2021-03-31 | $13.34M 10-Q · filed 2022-05-16 | $27.31M derived: sum of 2 quarters · filed 2022-05-16 | $41.27M derived: sum of 3 quarters · filed 2022-05-16 | $53.33M derived: sum of 4 quarters · filed 2022-05-16 | |||||||||||
| 2020-12-31 | $13.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $27.94M derived: sum of 2 quarters · filed 2022-03-30 | $39.99M derived: sum of 3 quarters · filed 2022-03-30 | $52.70M 10-K · filed 2022-03-30 | |||||||||||
| 2020-09-30 | $13.97M 10-Q · filed 2021-11-08 | $26.02M derived: sum of 2 quarters · filed 2021-11-08 | $38.73M 10-Q · filed 2021-11-08 | $48.94M derived: sum of 4 quarters · filed 2021-11-08 | |||||||||||
| 2020-06-30 | $12.05M 10-Q · filed 2021-08-13 | $24.76M 10-Q · filed 2021-08-13 | $34.97M derived: sum of 3 quarters · filed 2021-08-13 | $43.61M derived: sum of 4 quarters · filed 2021-08-13 | |||||||||||
| 2020-03-31 | $12.71M 10-Q · filed 2021-05-06 | $22.92M derived: sum of 2 quarters · filed 2021-05-06 | $31.56M derived: sum of 3 quarters · filed 2021-05-06 | $41.56M derived: sum of 4 quarters · filed 2021-05-06 | |||||||||||
| 2019-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $18.86M derived: sum of 2 quarters · filed 2021-03-01 | $28.86M derived: sum of 3 quarters · filed 2021-03-01 | $38.33M 10-K · filed 2021-03-01 | |||||||||||
| 2019-09-30 | $8.64M 10-Q · filed 2020-11-05 | $18.64M derived: sum of 2 quarters · filed 2020-11-05 | $28.11M 10-Q · filed 2020-11-05 | $36.31M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||
| 2019-06-30 | $10.00M 10-Q · filed 2020-08-06 | $19.47M 10-Q · filed 2020-08-06 | $27.67M derived: sum of 3 quarters · filed 2021-03-01 | $35.94M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||
| 2019-03-31 | $9.48M 10-Q · filed 2020-05-07 | $17.68M derived: sum of 2 quarters · filed 2021-03-01 | $25.94M derived: sum of 3 quarters · filed 2021-03-01 | $33.43M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||
| 2018-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.46M derived: sum of 2 quarters · filed 2021-03-01 | $23.95M derived: sum of 3 quarters · filed 2021-03-01 | $34.13M 10-K · filed 2021-03-01 | |||||||||||
| 2018-09-30 | $8.26M 10-Q · filed 2019-11-07 | $15.75M derived: sum of 2 quarters · filed 2019-11-07 | $25.93M 10-Q · filed 2019-11-07 | $37.12M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||
| 2018-06-30 | $7.49M 10-Q · filed 2019-08-08 | $17.67M 10-Q · filed 2019-08-08 | $28.85M derived: sum of 3 quarters · filed 2020-03-02 | $39.96M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||
| 2018-03-31 | $10.18M 10-Q · filed 2019-05-08 | $21.36M derived: sum of 2 quarters · filed 2020-03-02 | $32.47M derived: sum of 3 quarters · filed 2020-03-02 | $43.30M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||
| 2017-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $22.29M derived: sum of 2 quarters · filed 2020-03-02 | $33.12M derived: sum of 3 quarters · filed 2020-03-02 | $45.08M 10-K · filed 2020-03-02 | |||||||||||
| 2017-09-30 | $11.11M 10-Q · filed 2018-11-09 | $21.94M derived: sum of 2 quarters · filed 2018-11-09 | $33.90M 10-Q · filed 2018-11-09 | $43.29M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||
| 2017-06-30 | $10.83M 10-Q · filed 2018-08-08 | $22.80M 10-Q · filed 2018-08-08 | $32.19M derived: sum of 3 quarters · filed 2019-03-05 | $41.16M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||
| 2017-03-31 | $11.97M 10-Q · filed 2018-05-10 | $21.36M derived: sum of 2 quarters · filed 2019-03-05 | $30.33M derived: sum of 3 quarters · filed 2019-03-05 | $159.56M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||
| 2016-12-31 | $9.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $18.36M derived: sum of 2 quarters · filed 2019-03-05 | $147.59M derived: sum of 3 quarters · filed 2019-03-05 | $157.79M 10-K · filed 2019-03-05 | |||||||||||
| 2016-09-30 | $8.97M 10-Q · filed 2017-11-06 | $138.20M derived: sum of 2 quarters · filed 2017-11-06 | $148.40M 10-Q · filed 2017-11-06 | $156.54M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||
| 2016-06-30 | $129.23M 10-Q · filed 2017-07-31 | $139.43M 10-Q · filed 2017-07-31 | $147.57M derived: sum of 3 quarters · filed 2018-03-01 | $164.54M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||
| 2016-03-31 | $10.20M 10-Q · filed 2017-05-01 | $18.34M derived: sum of 2 quarters · filed 2018-03-01 | $35.31M derived: sum of 3 quarters · filed 2018-03-01 | $42.73M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||
| 2015-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $25.11M derived: sum of 2 quarters · filed 2018-03-01 | $32.54M derived: sum of 3 quarters · filed 2018-03-01 | $106.78M 10-K · filed 2018-03-01 | |||||||||||
| 2015-09-30 | $16.97M 10-Q · filed 2016-11-09 | $24.39M derived: sum of 2 quarters · filed 2016-11-09 | $98.64M 10-Q · filed 2016-11-09 | $106.73M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||
| 2015-06-30 | $7.42M 10-Q · filed 2016-08-09 | $81.67M 10-Q · filed 2016-08-09 | $89.76M derived: sum of 3 quarters · filed 2017-02-16 | $99.49M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||
| 2015-03-31 | $74.25M 10-Q · filed 2016-05-10 | $82.33M derived: sum of 2 quarters · filed 2017-02-16 | $92.07M derived: sum of 3 quarters · filed 2017-02-16 | $100.41M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||
| 2014-12-31 | $8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $17.82M derived: sum of 2 quarters · filed 2017-02-16 | $26.16M derived: sum of 3 quarters · filed 2017-02-16 | $32.71M 10-K · filed 2017-02-16 | |||||||||||
| 2014-09-30 | $9.73M 10-Q · filed 2015-11-02 | $18.08M derived: sum of 2 quarters · filed 2015-11-02 | $24.62M 10-Q · filed 2015-11-02 | $27.34M derived: sum of 4 quarters · filed 2016-02-24 | |||||||||||
| 2014-06-30 | $8.35M 10-Q · filed 2015-08-10 | $14.89M 10-Q · filed 2015-08-10 | $17.61M derived: sum of 3 quarters · filed 2016-02-24 | $23.85M derived: sum of 4 quarters · filed 2016-02-24 | |||||||||||
| 2014-03-31 | $6.54M 10-Q · filed 2015-05-07 | $9.26M derived: sum of 2 quarters · filed 2016-02-24 | $15.51M derived: sum of 3 quarters · filed 2016-02-24 | $30.28M derived: sum of 4 quarters · filed 2016-02-24 | $261.74M 10-Q · filed 2014-05-08 | ||||||||||
| 2013-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $8.97M derived: sum of 2 quarters · filed 2016-02-24 | $23.74M derived: sum of 3 quarters · filed 2016-02-24 | $42.85M 10-K · filed 2016-02-24 | $255.20M 10-K · filed 2014-03-03 | ||||||||||
| 2013-09-30 | $6.25M 10-Q · filed 2014-10-30 | $21.02M derived: sum of 2 quarters · filed 2014-10-30 | $40.13M 10-Q · filed 2014-10-30 | $75.12M derived: sum of 4 quarters · filed 2015-02-26 | $252.48M 10-Q · filed 2013-10-22 | ||||||||||
| 2013-06-30 | $14.78M 10-Q · filed 2014-08-07 | $33.89M 10-Q · filed 2014-08-07 | $68.87M derived: sum of 3 quarters · filed 2015-02-26 | $85.08M derived: sum of 4 quarters · filed 2015-02-26 | $246.23M 10-Q · filed 2013-08-08 | ||||||||||
| 2013-03-31 | $19.11M 10-Q · filed 2014-05-08 | $54.09M derived: sum of 2 quarters · filed 2015-02-26 | $70.31M derived: sum of 3 quarters · filed 2015-02-26 | $88.57M derived: sum of 4 quarters · filed 2015-02-26 | $231.46M 10-Q · filed 2013-05-07 | ||||||||||
| 2012-12-31 | $34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $51.20M derived: sum of 2 quarters · filed 2015-02-26 | $69.46M derived: sum of 3 quarters · filed 2015-02-26 | $83.45M 10-K · filed 2015-02-26 | $212.34M 10-K · filed 2013-03-18 | ||||||||||
| 2012-09-30 | $16.21M 10-Q · filed 2013-10-22 | $34.48M derived: sum of 2 quarters · filed 2013-10-22 | $48.46M 10-Q · filed 2013-10-22 | $61.11M derived: sum of 4 quarters · filed 2014-03-03 | $177.36M 10-Q · filed 2012-11-08 | ||||||||||
| 2012-06-30 | $18.26M 10-Q · filed 2013-08-08 | $32.25M 10-Q · filed 2013-08-08 | $44.90M derived: sum of 3 quarters · filed 2014-03-03 | $55.57M derived: sum of 4 quarters · filed 2014-03-03 | $161.15M 10-Q/A · filed 2012-08-28 | ||||||||||
| 2012-03-31 | $13.98M 10-Q · filed 2013-05-07 | $26.64M derived: sum of 2 quarters · filed 2014-03-03 | $37.30M derived: sum of 3 quarters · filed 2014-03-03 | $46.43M derived: sum of 4 quarters · filed 2014-03-03 | $142.88M 10-Q · filed 2012-05-03 | ||||||||||
| 2011-12-31 | $12.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $23.32M derived: sum of 2 quarters · filed 2014-03-03 | $32.44M derived: sum of 3 quarters · filed 2014-03-03 | $57.08M 10-K · filed 2014-03-03 | $128.90M 10-K · filed 2012-02-29 | ||||||||||
| 2011-09-30 | $10.67M 10-Q · filed 2012-11-08 | $19.79M derived: sum of 2 quarters · filed 2012-11-08 | $44.43M 10-Q · filed 2012-11-08 | ||||||||||||
| 2011-06-30 | $9.13M 10-Q/A · filed 2012-08-28 | $33.77M 10-Q/A · filed 2012-08-28 | |||||||||||||
| 2011-03-31 | $24.64M 10-Q · filed 2012-05-03 | ||||||||||||||
| 2011-01-12 | $17.50M 10-K · filed 2014-03-03 | ||||||||||||||
| 2011-01-06 | $17.50M 10-K · filed 2013-03-18 | ||||||||||||||
| 2010-12-31 | $12.91M 10-K · filed 2013-03-18 | ||||||||||||||
| 2009-12-31 | $4.56M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |